Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Approvals, Complete Responses Hit Record In FY 2016

Executive Summary

FDA's Office of Generic Drugs completes its best year of the GDUFA era.


Related Content

FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
ANDA Approvals Break Record, May Set New Normal
Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?
FDA Hiring Campaign Continues; Goal Is Addressing Pending ANDAs
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
EpiPen Generics: Woodcock Explains Injector Studies
ANDA Approvals, Submissions Decline With New Review Goal Coming
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
GDUFA Performance Goals For Fiscal Years 2013-2017





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts